{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:17:29Z","timestamp":1789899449105,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Capital Clinical Characteristic Application Research","award":["Z151100004015121"],"award-info":[{"award-number":["Z151100004015121"]}]},{"name":"Beijing Hope Run Special Fund","award":["LC2014L13"],"award-info":[{"award-number":["LC2014L13"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-017-3810-7","type":"journal-article","created":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T07:19:51Z","timestamp":1512371991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical significance of PCDH10 promoter methylation in diffuse large B-cell lymphoma"],"prefix":"10.1186","volume":"17","author":[{"given":"Wenting","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7301-4118","authenticated-orcid":false,"given":"Jianming","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,4]]},"reference":[{"issue":"2","key":"3810_CR1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4161\/cam.5.2.14374","volume":"5","author":"SY Kim","year":"2011","unstructured":"Kim SY, Yasuda S, Tanaka H, Yamagata K, Kim H. Non-clustered protocadherin. Cell Adhes Migr. 2011;5(2):97\u2013105.","journal-title":"Cell Adhes Migr"},{"issue":"7","key":"3810_CR2","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/sj.onc.1209154","volume":"25","author":"J Ying","year":"2006","unstructured":"Ying J, Li H, Seng TJ, Langford C, Srivastava G, Tsao SW, Putti T, Murray P, Chan AT, Tao Q. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene. 2006;25(7):1070\u201380.","journal-title":"Oncogene"},{"issue":"2","key":"3810_CR3","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1053\/j.gastro.2008.10.050","volume":"136","author":"J Yu","year":"2009","unstructured":"Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, Tian LW, Wong YP, Tong JH, Ying JM, et al. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology. 2009;136(2):640\u201351. e641","journal-title":"Gastroenterology"},{"issue":"2","key":"3810_CR4","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3892\/or.2015.4056","volume":"34","author":"Y Xu","year":"2015","unstructured":"Xu Y, Yang Z, Yuan H, Li Z, Li Y, Liu Q, Chen J. PCDH10 inhibits cell proliferation of multiple myeloma via the negative regulation of the Wnt\/\u03b2-catenin\/BCL-9 signaling pathway. Oncol Rep. 2015;34(2):747\u201354.","journal-title":"Oncol Rep"},{"issue":"5","key":"3810_CR5","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3233\/CBM-150496","volume":"15","author":"YC Hou","year":"2015","unstructured":"Hou YC, Deng JY, Zhang RP, Xie XM, Cui JL, WP W, Hao XS, Liang H. Evaluating the clinical feasibility: the direct bisulfite genomic sequencing for examination of methylated status of protocadherin10 (PCDH10) promoter to predict the prognosis of gastric cancer. Cancer Biomarkers. 2015;15(5):567\u201373.","journal-title":"Cancer Biomarkers"},{"issue":"10","key":"3810_CR6","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/cam4.507","volume":"4","author":"H Harada","year":"2015","unstructured":"Harada H, Miyamoto K, Yamashita Y, Taniyama K, Mihara K, Nishimura M, Okada M. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer. Cancer Medicine. 2015;4(10):1536\u201346.","journal-title":"Cancer Medicine"},{"issue":"4","key":"3810_CR7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235\u201342.","journal-title":"N Engl J Med"},{"issue":"14","key":"3810_CR8","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","volume":"28","author":"M Ziepert","year":"2010","unstructured":"Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, Loeffler M. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373\u201380.","journal-title":"J Clin Oncol"},{"issue":"22","key":"3810_CR9","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","volume":"359","author":"G Lenz","year":"2008","unstructured":"Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313\u201323.","journal-title":"N Engl J Med"},{"issue":"19","key":"3810_CR10","doi-asserted-by":"crossref","first-page":"6112","DOI":"10.1158\/1078-0432.CCR-11-1073","volume":"17","author":"JW Friedberg","year":"2011","unstructured":"Friedberg JW. New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice. Clin Cancer Res. 2011;17(19):6112\u20137.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3810_CR11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1365-2141.2007.06512.x","volume":"136","author":"J Ying","year":"2007","unstructured":"Ying J, Gao Z, Li H, Srivastava G, Murray PG, Goh HK, Lim CY, Wang Y, Marafioti T, Mason DY, et al. Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies. Br J Haematol. 2007;136(6):829\u201332.","journal-title":"Br J Haematol"},{"issue":"25","key":"3810_CR12","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937\u201347.","journal-title":"N Engl J Med"},{"issue":"5","key":"3810_CR13","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","volume":"105","author":"S Monti","year":"2005","unstructured":"Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, Wu B, Pasqualucci L, Neuberg D, Aguiar RC, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105(5):1851\u201361.","journal-title":"Blood"},{"issue":"11","key":"3810_CR14","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2013-07-509885","volume":"123","author":"N Chambwe","year":"2014","unstructured":"Chambwe N, Kormaksson M, Geng H, De S, Michor F, Johnson NA, Morin RD, Scott DW, Godley LA, Gascoyne RD, et al. Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood. 2014;123(11):1699\u2013708.","journal-title":"Blood"},{"issue":"11","key":"3810_CR15","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/gcc.22098","volume":"52","author":"G Narayan","year":"2013","unstructured":"Narayan G, Xie D, Freddy AJ, Ishdorj G, Do C, Satwani P, Liyanage H, Clark L, Kisselev S, Nandula SV, et al. PCDH10 promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis. Genes Chromosomes Cancer. 2013;52(11):1030\u201341.","journal-title":"Genes Chromosomes Cancer"},{"issue":"20","key":"3810_CR16","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1182\/blood-2010-05-285320","volume":"116","author":"R Shaknovich","year":"2010","unstructured":"Shaknovich R, Geng H, Johnson NA, Tsikitas L, Cerchietti L, Greally JM, Gascoyne RD, Elemento O, Melnick A. DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood. 2010;116(20):e81\u20139.","journal-title":"Blood"},{"key":"3810_CR17","doi-asserted-by":"crossref","unstructured":"Bognar MK, Vincendeau M, Erdmann T, Seeholzer T, Grau M, Linnemann JR, Ruland J, Scheel CH, Lenz P, Ott G, et al. Oncogenic CARMA1 couples NF-kappaB and beta-catenin signaling in diffuse large B-cell lymphomas. Oncogene. 2016;","DOI":"10.1038\/onc.2015.493"},{"issue":"6","key":"3810_CR18","first-page":"1433","volume":"5","author":"X Ge","year":"2012","unstructured":"Ge X, Lv X, Feng L, Liu X, Wang X. High expression and nuclear localization of beta-catenin in diffuse large B-cell lymphoma. Mol Med Rep. 2012;5(6):1433\u20137.","journal-title":"Mol Med Rep"},{"issue":"2","key":"3810_CR19","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3892\/mmr.2014.2285","volume":"10","author":"Z Li","year":"2014","unstructured":"Li Z, Yang Z, Peng X, Li Y, Liu Q, Chen J. Nuclear factor-kappaB is involved in the protocadherin-10-mediated pro-apoptotic effect in multiple myeloma. Mol Med Rep. 2014;10(2):832\u20138.","journal-title":"Mol Med Rep"},{"issue":"12","key":"3810_CR20","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1200\/JCO.2005.07.155","volume":"23","author":"A Lopez-Guillermo","year":"2005","unstructured":"Lopez-Guillermo A, Colomo L, Jimenez M, Bosch F, Villamor N, Arenillas L, Muntanola A, Montoto S, Gine E, Colomer D, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(12):2797\u2013804.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3810-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T07:20:06Z","timestamp":1512372006000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3810-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3810"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3810-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"815"}}